Pediatric Vaccines Market Research Report - Forecast till 2030

Pediatric Vaccines Market Research Report: Information by Type (Monovalent Vaccines and Multivalent Vaccines), Technology (Live Attenuated, Inactivated, Subunits, Toxoids, Conjugates and others), Application (Polio, Diphtheria-Tetanus-Acellular Pertussis, Haemophilus Influenzae type B, MMR, Hepatitis B, Pneumococcal Vaccine and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2030

ID: MRFR/Pharma/4323-HCR | December 2022 | Region: Global | 95 Pages         

Pediatric Vaccines Market

Pediatric Vaccines Market to register a CAGR of 9.90% and reach a value of USD 35.52 Billion by 2027.

Segmentation

by Type Monovalent Vaccines Multivalent Vaccines
by Technology Live Attenuated Inactivated Subunits Toxoids Conjugates Others
by Application Polio Diphtheria-Tetanus-Acellular Pertussis (DTaP) Haemophilus Influenzae Type B (Hib) MMR (Mumps Measles and Rubella) Hepatitis B Pneumococcal Vaccine Others

Key Players

  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Merck & Co.
  • Pfizer Inc.
  • Grifols
  • Serum Institute of India Pvt. Ltd.
  • AstraZeneca
  • Cadila Healthcare Ltd
  • Indian Immunologicals Limited
  • CSL Limited

Drivers

  • increasing government support
  • increasing awareness
Speak to Analyst Request a Free Sample

Pediatric Vaccines Market Overview

The pediatric vaccines market is expected to reach USD 35.52 Billion by 2030 at 9.90% CAGR during the forecast period 2022-2030. Pediatric vaccines are those given to children to prevent them from getting a variety of non-infectious and infectious diseases. These vaccinations are viruses that have been heat-killed or inactivated, meaning they have lost their pathogenicity, or capacity to cause disease. Furthermore, these inactivated antigens might trigger the immune system to create antibodies against the virus that has infected the body. As a result, they aid the immune system in future protection against infectious and non-infectious disorders. Immunization currently saves the lives of an estimated 2-3 million people per year. Factors such as global initiatives conducted by key companies in producing innovative vaccines and increased government backing are driving the global pediatric vaccines market. Furthermore, rising public awareness of the benefits of vaccination in disease prevention is expected to drive market expansion.


 
People are traveling much more frequently and over much longer distances than in the past, living in more densely populated places, and coming into closer contact with wild animals, so the potential for new infectious diseases to spread quickly and trigger worldwide epidemics is a serious concern. Furthermore, diseases could occur as a result of the deliberate introduction of pathogens into human, animal, or plant populations for terrorist goals. Anthrax, smallpox, and tularemia are among these diseases. Some of the major reasons fueling the market's growth are an increase in government and non-government funding for research and development.

Segmentation


The Pediatric Vaccines Global Market has been segmented based on type, technology, application, and region.


The global market, based on type, has been divided into monovalent vaccines and multivalent vaccines.


The global market, based on technology, has been segmented into live attenuated, inactivated, subunits, toxoids, conjugates, and others. The live attenuated segment is expected to hold a major share in the market due to the wide range of its application.


The global market, based on application, has been segmented into polio, diphtheria-tetanus-acellular pertussis (DTaP), Haemophilus influenzae type B (Hib), MMR (Mumps, Measles, and Rubella), Hepatitis B, pneumococcal vaccine, and others.


The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The pediatric vaccines market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European pediatric vaccines market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The pediatric vaccines market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pediatric vaccines market in the Middle East & Africa has been divided into the Middle East and Africa.


Key Players


The Key Players operating in the Pediatric Vaccines Global Market are Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Grifols, Serum Institute of India Pvt. Ltd., AstraZeneca, Cadila Healthcare Ltd, Indian Immunologicals Limited, and CSL Limited.


Regional Market Summary


Global Pediatric Vaccines Market Share, by Region, 2018 (%)  Pediatric Vaccines Market


Source: World Health Organization (WHO)


The market in the Americas is expected to dominate the global pediatric vaccines market due to the presence of major established players in the region and increasing R&D expenses.


Europe is expected to hold the second-largest position in the global market. This can be attributed to the presence of a well-established healthcare system and an increase in infectious diseases.


Asia-Pacific is expected to be the fastest-growing region owing to the growing population and increasing awareness about the vaccine’s products.


The pediatric vaccines market in the Middle East & Africa is projected to account for the least share of the market due to the low per capita disposable income in the region.


Global Pediatric Vaccines Market, by Type



  • Monovalent Vaccines

  • Multivalent Vaccines


Global Pediatric Vaccines Market, by Technology



  • Live Attenuated

  • Inactivated

  • Subunits

  • Toxoids

  • Conjugates

  • Others


Global Pediatric Vaccines Market, by Application



  • Polio

  • Diphtheria-Tetanus-Acellular Pertussis (DTaP)

  • Haemophilus Influenzae Type B (Hib)

  • MMR (Mumps, Measles, and Rubella)

  • Hepatitis B

  • Pneumococcal Vaccine

  • Others


Global Pediatric Vaccines Market, by Region




  • Americas




    • North America




      • US




      • Canada






    • Latin America








  • Europe




    • Western Europe




      • Germany




      • France




      • Italy




      • Spain




      • UK




      • Rest of Western Europe






    • Eastern Europe








  • Asia-Pacific




    • Japan




    • China




    • India




    • Australia




    • South Korea




    • Rest of Asia-Pacific








  • Middle East & Africa




    • Middle East




    • Africa






Recent Development


Merck released top-line findings from the pivotal PNEU-PED (V114-029) study in August 2021, which assessed the immunogenicity, safety, and tolerability of VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) in healthy babies aged 42-90 days. At 2, 4, 6, and 12-15 months of age, babies were given a 4-dose regimen of either VAXNEUVANCE or the approved 13-valent pneumococcal conjugate vaccine (PCV13).
 
Merck announced the acquisition of Themis, a privately held company that specializes in vaccines and immune-modulating drugs for infectious diseases and cancer, in June 2020.

Intended Audience

  • Research and development (R&D) companies

  • Pediatric Vaccines manufacturing companies

  • Government research institutes

  • Academic institutes and universities

  • Venture capitalists



Report Scope:

Report Attribute/Metric Details
  Market Size   35.52 Billion
  CAGR   9.90%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Technology, Application
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Grifols, Serum Institute of India Pvt. Ltd., AstraZeneca, Cadila Healthcare Ltd, Indian Immunologicals Limited, and CSL Limited.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Increasing awareness regarding the benefits of vaccination in prevention of diseases is anticipated to fuel market growth


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Pediatric Vaccines Market is projected to grow at a 9.90 % CAGR between 2022-2030.

The Americas is expected to lead the Pediatric Vaccines Market.

It is widely used for hepatitis B, polio, MMR, and others.

Key players in the Pediatric Vaccines Market include CSL Limited, Indian Immunologicals Limited, Cadila Healthcare Ltd, AstraZeneca, Serum Institute of India Pvt. Ltd., Grifols, Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, and Sanofi S.A.

Different strategies used by market players to create a dominance in the Pediatric Vaccines Market include product launch, strategic alliances, mergers, and expansions.